Nucl Med Mol Imaging.  2012 Jun;46(2):129-133.

Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease

Affiliations
  • 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
  • 2Department of Nuclear Medicine and Center for PET/CT, Zentralklinik Bad Berka, 99437 Bad Berka, Germany. richard.baum@zentralklinik.de

Abstract

Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome with a variety of benign and malignant tumors such as retinal and central nervous system hemangioblastomas, endolymphatic sac tumors, renal cysts and tumors, pancreatic cysts and tumors, pheochromocytomas, and epididymal cystadenomas. Cross-sectional modalities (computed tomography and magnetic resonance imaging) as well as ultrasound play a major role in the initial evaluation and follow-up of the various manifestations of VHL disease. Ga-68-labeled somatostatin receptor analogs already have a significant role in the diagnosis, staging, and therapy management of neuroendocrine neoplasms and neural crest tumors. Herein, we report a case presenting a variety of malignancies in VHL and showing the usefulness of Ga-68 somatostatin receptor PET/CT as a one-stop-shop imaging modality in the management of VHL disease.

Keyword

Ga-68 DOTA-TOC PET/CT; Ga-68DOTA-TATE PET/CT; Ga-68DOTA-NOC PET/CT; von Hippel-Lindau disease; Hemangioblastoma; Pheochromocytoma

MeSH Terms

Central Nervous System
Cystadenoma
Endolymphatic Sac
Follow-Up Studies
Hemangioblastoma
Magnetic Resonance Spectroscopy
Neural Crest
Pancreatic Cyst
Pheochromocytoma
Receptors, Somatostatin
Retinaldehyde
Somatostatin
von Hippel-Lindau Disease
Receptors, Somatostatin
Retinaldehyde
Somatostatin
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr